MDXG Stock Recent News

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the placental biologics company.

MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Chase Knickerbocker - Craig-Hallum Capital Group Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Operator Greetings and welcome to the MiMedx Second Quarter 2024 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products Limited market release marks first xenograft addition to Company's portfolio of leading Wound and Surgical products

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12 , Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024 , at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2024.

Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.

MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript